Welcome to Anergis
Anergis is a clinical-stage biopharmaceutical company based in Switzerland.
Anergis discovers and develops proprietary synthetic allergy vaccines with the aim to provide allergy patients and doctors with a significantly improved treatment option: ultra-fast desensitization.
Anergis COP allergy vaccines are pharmaceutical-grade products based on Contiguous Overlapping Peptides (COPs) and only need to be administered for 2 months in order to achieve long-lasting desensitization.
If you are interested to participate in one of our clinical trials, please send an email to info@anergis.ch
13 June 2013
21 February 2013
14 February 2013
23 January 2013
08 November 2012
06 November 2012
see details
Anergis Files Provisional U.S. Patent on AllerDM Dust Mite Allergy Treatment
21 February 2013
Anergis Presents Preclinical Data of its Ragweed Allergy Vaccine Candidate AllerR
14 February 2013
Anergis Expands Management Team
23 January 2013
Anergis Obtains U.S. Patent for Lead Product AllerT
08 November 2012
Long-Term Immunomodulation Induced by AllerT Now Extends to the 4th Year
06 November 2012
Anergis starts European Phase IIb Clinical Trial with AllerT
see details